Camaschella Clara
Vita Salute University and IRCCS Ospedale San Raffaele, Milan, Italy.
Blood Rev. 2017 Jul;31(4):225-233. doi: 10.1016/j.blre.2017.02.004. Epub 2017 Feb 13.
Recent advances in iron metabolism have stimulated new interest in iron deficiency (ID) and its anemia (IDA), common conditions worldwide. Absolute ID/IDA, i.e. the decrease of total body iron, is easily diagnosed based on decreased levels of serum ferritin and transferrin saturation. Relative lack of iron in specific organs/tissues, and IDA in the context of inflammatory disorders, are diagnosed based on arbitrary cut offs of ferritin and transferrin saturation and/or marker combination (as the soluble transferrin receptor/ferritin index) in an appropriate clinical context. Most ID patients are candidate to traditional treatment with oral iron salts, while high hepcidin levels block their absorption in inflammatory disorders. New iron preparations and new treatment modalities are available: high-dose intravenous iron compounds are becoming popular and indications to their use are increasing, although long-term side effects remain to be evaluated.
铁代谢的最新进展激发了人们对缺铁(ID)及其贫血(IDA)的新兴趣,这是全球常见的病症。绝对性ID/IDA,即全身铁含量降低,可根据血清铁蛋白水平和转铁蛋白饱和度降低轻松诊断。特定器官/组织中铁的相对缺乏以及炎症性疾病中的IDA,是在适当的临床背景下,根据铁蛋白和转铁蛋白饱和度的任意临界值和/或标志物组合(如可溶性转铁蛋白受体/铁蛋白指数)来诊断的。大多数ID患者适合采用口服铁盐的传统治疗方法,而高血浆铁调素水平会在炎症性疾病中阻碍其吸收。有了新的铁制剂和新的治疗方式:高剂量静脉铁化合物正变得越来越普遍,其使用指征也在增加,尽管长期副作用仍有待评估。